Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy

Tisagenlecleucel (tisa-cel) and brexucabtagene autoleucel (brexu-cel) are approved CD19 chimeric antigen receptor T-cell therapy (CAR T) products for young adults (YA) with relapsed/refractory B-cell acute lymphoblastic leukemia. A distinct analysis of YAs receiving commercial CD19 CAR T has not been reported. Using retrospective data from the Pediatric Real-World CAR T Consortium and the Real-World Outcomes of CAR T in Adult ALL collaboration, we describe the efficacy and safety of tisa-cel and brexu-cel in 70 YAs (18-26 years; tisa-cel, n = 50; brexu-cel, n = 20). Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were observed more frequently for brexu-cel vs tisa-cel (CRS, 85% vs 56%; ICANS, 40% vs 18%). Complete response rates were similar between products at 80% for brexu-cel and 88% for tisa-cel. Relapse-free survival (RFS) at 12 months was 46% for brexu-cel and 36% for tisa-cel. Durability of remission over 12 months was 61% for brexu-cel vs 41% for tisa-cel; 12-month overall survival (OS) for brexu-cel was 84% vs 68% for tisa-cel. In multivariate analysis, low disease burden was associated with improved OS, whereas inotuzumab before CAR T was associated with inferior outcomes. This study demonstrates comparable real-world efficacy among YAs receiving CD19 CAR T irrespective of CAR T construct; however, rates of toxicity seem higher with brexu-cel.

Authors

Institutions

Publication Details

Journal
Blood Advances
Published
2025-03-24
DOI
https://doi.org/10.1182/bloodadvances.2024014846
Citations
8
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
8.36
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy

Michelle L. Hermiston, Lori S. Muffly, Rawan Faramand, Erin Hall et al.
8 citations
Blood Advances
CAR-T cell therapy research
8.36
article

Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy

Michelle L. Hermiston, Lori S. Muffly, Rawan Faramand, Erin Hall, Margaret L. MacMillan, Sunil S. Raikar, George Yaghmour, Paul Shaughnessy, Kevin O. McNerney, Samuel John, Marlise Rachael Luskin, Bijal Shah, Marc S. Schwartz, Vanessa A. Fabrizio, Muna Qayed, Tamer Adel Othman, Ibrahim Taha Aldoss, Hannah Lust, Gregory W. Roloff, Noam E. Kopmar, Prakash Satwani, Evan Chris Chen, Christina Baggott, Stacy Cooper, Soyang Kwon, John Mathews, Muthu Sendhil Kumaran, Liora M. Schultz, Vamsi Kota, Susanne H.C. Baumeister, Veronika Bachanová, Ryan D. Cassaday, Sean Tracy, Abdullah Ladha, Anjali S. Advani, Julie-An Talano, Jenna Rossoff, Kate Miller, Nicole Karras, Amy Moskop, Nikeshan Jeyakumar, Kevin J. Curran, Amy Zhang, Khanh Nguyen, Christine L. Phillips
article en
8 citations

Abstract

Tisagenlecleucel (tisa-cel) and brexucabtagene autoleucel (brexu-cel) are approved CD19 chimeric antigen receptor T-cell therapy (CAR T) products for young adults (YA) with relapsed/refractory B-cell acute lymphoblastic leukemia. A distinct analysis of YAs receiving commercial CD19 CAR T has not been reported. Using retrospective data from the Pediatric Real-World CAR T Consortium and the Real-World Outcomes of CAR T in Adult ALL collaboration, we describe the efficacy and safety of tisa-cel and brexu-cel in 70 YAs (18-26 years; tisa-cel, n = 50; brexu-cel, n = 20). Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were observed more frequently for brexu-cel vs tisa-cel (CRS, 85% vs 56%; ICANS, 40% vs 18%). Complete response rates were similar between products at 80% for brexu-cel and 88% for tisa-cel. Relapse-free survival (RFS) at 12 months was 46% for brexu-cel and 36% for tisa-cel. Durability of remission over 12 months was 61% for brexu-cel vs 41% for tisa-cel; 12-month overall survival (OS) for brexu-cel was 84% vs 68% for tisa-cel. In multivariate analysis, low disease burden was associated with improved OS, whereas inotuzumab before CAR T was associated with inferior outcomes. This study demonstrates comparable real-world efficacy among YAs receiving CD19 CAR T irrespective of CAR T construct; however, rates of toxicity seem higher with brexu-cel.

Blood AdvancesVol. 9(11)
Northwestern University (US), University of Southern California (US), Cincinnati Children's Hospital Medical Center (US), Lurie Children's Hospital (US), Houston Methodist (US), City Of Hope National Medical Center (US), University of Minnesota (US), Cleveland Clinic (US), Children's Mercy Hospital (US), Memorial Sloan Kettering Cancer Center (US), Harvard University (US), Johns Hopkins University (US), Emory University (US), Palo Alto University (US), University of California, San Francisco (US), Medical College of Wisconsin (US), Augusta University (US), Columbia University Irving Medical Center (US), Johns Hopkins Medicine (US), University of Washington Medical Center (US), Moffitt Cancer Center (US), University of Chicago (US), Augusta University Health (US), Fred Hutch Cancer Center (US), Children's Hospital Colorado (US), Southwestern Medical Center (US), Sarah Cannon (US), Methodist Healthcare (US), Methodist Hospital (US), City of Hope (US), Aflac (United States) (US), Versiti Blood Center of Wisconsin (US), USC Norris Comprehensive Cancer Center (US), Dana-Farber Cancer Institute (US), Lurie Children's Hospital (US), Stanford Blood Center (US), University of Colorado Cancer Center (US), University of Minnesota Medical Center (US), UCSF Benioff Children's Hospital (US), Children's Healthcare of Atlanta (US), Cellular Research (United States) (US), Johns Hopkins Hospital (US), Southwestern Medical Center (US), University of Colorado Anschutz Medical Campus (US), University of San Francisco (US), University of Arkansas for Medical Sciences (US), The University of Texas Southwestern Medical Center (US), University of Colorado Denver (US), Stanford University (US)
Partnerships for the goals
Openalex Percentile: Top 2%
CAR-T cell therapy research
8.36
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.